CN105963595A - Auxiliary uric acid reducing tablet with antrodia camphorata and method for preparing auxiliary uric acid reducing tablet - Google Patents
Auxiliary uric acid reducing tablet with antrodia camphorata and method for preparing auxiliary uric acid reducing tablet Download PDFInfo
- Publication number
- CN105963595A CN105963595A CN201610490926.2A CN201610490926A CN105963595A CN 105963595 A CN105963595 A CN 105963595A CN 201610490926 A CN201610490926 A CN 201610490926A CN 105963595 A CN105963595 A CN 105963595A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- antrodia camphorata
- parts
- auxiliary
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 58
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 229940116269 uric acid Drugs 0.000 title claims abstract description 57
- 241001486992 Taiwanofungus camphoratus Species 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 32
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- 240000005739 Eurycoma longifolia Species 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 5
- 241001251949 Xanthium sibiricum Species 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 18
- 210000000952 spleen Anatomy 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 3
- 240000008042 Zea mays Species 0.000 abstract 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 3
- 235000005822 corn Nutrition 0.000 abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000005569 Gout Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 206010062575 Muscle contracture Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000006111 contracture Diseases 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010060710 Galactostasis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000008589 Cortex Fraxini Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an auxiliary uric acid reducing tablet with antrodia camphorata. The auxiliary uric acid reducing tablet comprises, by weight, 1-3 parts of antrodia camphorata powder, 7-10 parts of corn stigma, 3-5 parts of eurycoma longifolia jack, 1-3 parts of rhizoma smilacis glabrae and 2-4 parts of semen coicis. A method for preparing the auxiliary uric acid reducing tablet includes mixing the corn stigma, the eurycoma longifolia jack, the rhizoma smilacis glabrae and the semen coicis with one another to obtain first mixtures, then decocting the first mixtures by the aid of water to obtain liquid and concentrating the liquid to obtain extract paste; mixing the extract paste and the antrodia camphorata powder with each other to obtain second mixtures, drying and grinding the second mixtures to obtain powder, granulating the powder by the aid of wet processes and tabletting the powder to obtain the auxiliary uric acid reducing tablet. The auxiliary uric acid reducing tablet and the method have the advantages that patients are subjected to traditional Chinese medicine diagnosis and treatment, the antrodia camphorata and the corn stigma are used as main drugs, are assisted by the semen coicis and the rhizoma smilacis glabrae and are compatible with the eurycoma longifolia jack with an excellent effect of reducing uric acid, various components are matched with one another, synergistic effects can be realized, and accordingly effects of invigorating spleens to eliminate dampness and evacuate turbid and increasing discharge of the uric acid to reduce the uric acid can be realized.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of containing Antrodia Camphorata auxiliary uric acid resisting sheet and preparation method thereof.
Background technology
Uric acid is the metabolite of health, and the uric acid of normal person should be less than 200 ml/dl in blood, is arranged by urine
Except external.Due to life style and the change of diet structure, the prevalence of hyperuricemia of China ramps in recent years, guards and estimates
Meter is up to 1.2 hundred million patients, and progressively rejuvenation of falling ill, within less than 20 years old, crowd accounts for 2.4%～5.7%.Hyperuricemia with
Obesity, coronary heart disease, hypertension, diabetes, hyperlipemia, insulin resistant, chronic nephropathy etc. are relevant.It is generally acknowledged blood uric acid
Male more than 420 μm ol/L, women more than 360 μm ol/L time examine as hyperuricemia.This disease point constitutional and Secondary cases:
The former is more common in primary gout, and minority is congenital azymia or functional disorder, and the latter sees various chronic kidney disease, white
Disorders of blood, lymphoma and polycythemia vera etc..The method reducing uric acid, at present except low purine diet, restriction tobacco and wine, heavily fortified point
Holding motion and control outside body weight, a lot of patients also need drug administration.Wherein Sodium Bicarbonate Tablets, allopurinol and benzbromarone are the most
Conventional.The untoward reaction of western medicine hyperuricemia is relatively big, and after drug withdrawal the most repeatedly, Clinical practice is restricted.Chinese medicine is controlled
Treat hyperuricemia, gout determined curative effect, toxicity is few, demonstrates greater advantage, it is known that the single having uric acid resisting effect
Chinese medicine kind is more, as Radix Angelicae Sinensis, Herba Lycopi can suppress the synthesis of uric acid, Stigma Maydis, Semen Coicis, Herba Plantaginis, Rhizoma Smilacis Glabrae, Rhizoma Alismatis, Cortex Fraxini
Etc. the discharge that can increase uric acid；Select the Chinese medicine in integration of edible and medicinal herbs Chinese medicine with uric acid resisting effect, carried out scientific composition, used
Modern advanced pharmaceutical technology makes tablet, has uric acid resisting effect by laboratory observation.
Antrodia Camphorata: Taiwan special product Antrodia Camphorata, is described as " ruby in forest ", cold in nature, and acrid in the mouth is bitter micro-sweet, returns liver and gall
Lung meridian.There is heat-clearing and toxic substances removing, eliminating carbuncle eliminating stagnation, let out clearly effect of liver-fire, eliminating stasis to stop pain.Antrodia Camphorata contains abundant triterpenes chemical combination
Thing, has promotion cancer cell death, suppression hepatoma cell proliferation, repairs liver, promote the effect of body Liver and kidney metabolism, cattle
Antrodia camphorata polysaccharide can improve the immunologic function of body.
Stigma Maydis, sweet in the mouth, light, property is put down；Return kidney, liver, gallbladder meridian；Light weight oozes fall.There is inducing diuresis to remove edema, the merit of suppressing the hyperactive liver function of gallbladder promoting
Effect.Cure mainly edema, dribbling urination, jaundice, cholecystitis, cholelithiasis, hypertension, diabetes, galactostasis.Stigma Maydis returns bladder
Warp, diuretic and treating stranguria, be especially suitable for the puckery pain of oliguria with reddish urine of damp-heat in the urinary bladder, modern pharmacological research to show: Stigma Maydis is to people or rabbit
All there is diuresis, uric acid output can be increased.
Semen Coicis: slightly sweet flavor, feeble QI is cool, and property edges down and oozes, therefore the diuretic that can dry, wet with its will, therefore energy profit joint, except foot
Gas, controls flaccidity weak contracture arthralgia chiefly caused by damp pathogen, consumer edema pain, Semen Coicis both dispelling the wind and dampness pathogens, the most main muscular contracture ferrum contracture, it is impossible to bend and stretch, those invasion of the body by blended pathogenic wind and dampness,
Acute pain in the joints, must not bend and stretch, invasion of the body by blended pathogenic wind and dampness, health pain with restlessness, it is impossible to certainly change one's position, and private Semen Coicis how?Lid Semen Coicis sweet in the mouth gas and,
Turbid product in Qing, can spleen invigorating the moon, greatly benefit the intestines and stomach.Curing mainly splenoasthenic diarrhea, cause into edema, rheumatism dish delays, and causes into brothers unable, it is impossible to bend
Stretch.
Rhizoma Smilacis Glabrae: Gan Danping, returns liver, stomach warp；Spleen channel.Function: removing toxic substances, dehumidifying, profit joint.Cure mainly: control syphilis, stranguria with turbid discharge,
Muscles and bones spasm and pain, tinea pedis, treat furuncle, carbuncle, scrofula, the limbs contracture caused by syphilis and mercurialism, bones and muscles pain.Rhizoma Smilacis Glabrae can be good for
Taste, curing rheumatism, the strong then battalion of taste defend from, rheumatism goes then muscles and bones profit.The traditional Chinese medical science thinks that Poria slightly sweet flavor is put down, and enters the heart, lung, spleen
Warp.There is eliminating dampness and diuresis, invigorating the spleen and regulating the stomach, effect of mind tranquilizing and the heart calming.Modern pharmacological research shows have diuresis, increase urate excretion
Effect.
Eurycoma longifolia: bitter in the mouth, cool in nature, heat clearing away, preventing the attack (or recurrence) of malaria, dampness removing jaundice eliminating, tonifying YANG.Treatment gout Britain draft scholar Kamal
The medicine scholar of doctor Ketuly and academy of science of Malaysia chemical composition to Ali in the laboratory of rainforest medical herbs company
Being analyzed, find that it contains the natural phytochemicals of a kind of probenecid, this composition can effectively regulate human body
Endocrine, suppression uric acid synthesis, make uric acid not be deposited in the positions such as human synovial, cartilage, soft tissue with the form of sodium salt crystal.
Medicine scholars have collected 100 patient with gout in various degree and have done clinical trial.Result is: take its experimenter after three days
Pain substantially alleviates, the red and swollen all disappearances of posterior joint in a week.Found by the uric acid level of detection experimenter, after taking one week,
The uric acid level having 86 experimenters raises.Medicine scholar thinks that uric acid level rising is because Ali and will be deposited on joint and cartilage group
Uric acid crystal in knitting melts and causes concentration to increase.After surrounding, when uric acid concentration is diluted and is excreted, uric acid level is then
Drop under 0.42 mM (standard value)；Remaining 14 severe patient with gout just occurs case above after taking eight weeks.?
Go out conclusion: Eurycoma longifolia has significant curative effect to goat.
Summary of the invention
It is an object of the invention to provide a kind of containing Antrodia Camphorata auxiliary uric acid resisting sheet and preparation method thereof, pass through Chinese medicine
Opinion control, with Antrodia Camphorata, Stigma Maydis as principal agent, be aided with Semen Coicis, Rhizoma Smilacis Glabrae, then the east leather Ah that compatibility uric acid resisting effect is stronger
In, cooperate between each composition, play cooperative effect, there is invigorating the spleen for eliminating dampness row turbid, increase uric acid discharge and reach uric acid resisting
Effect.
For achieving the above object, the present invention adopts the following technical scheme that
A kind of containing Antrodia Camphorata auxiliary uric acid resisting sheet, medicinal raw material used by it includes by weight: Antrodia Camphorata powder 1-3 part, Semen Maydis
Palpus 7 ~ 10 parts, Eurycoma longifolia 3 ~ 5 parts, Rhizoma Smilacis Glabrae 1 ~ 3 part, Semen Coicis 2 ~ 4 parts.
Preferably, a kind of containing Antrodia Camphorata auxiliary uric acid resisting sheet, medicinal raw material used includes by weight: Antrodia Camphorata powder 2
Part, Stigma Maydis 8 parts, Eurycoma longifolia 4 parts, Rhizoma Smilacis Glabrae 2 parts, Semen Coicis 3 parts.
Preparation method containing Antrodia Camphorata auxiliary uric acid resisting sheet comprises the steps: as mentioned above
Step 1): pulverized by Antrodia Camphorata, crosses 80-100 mesh sieve, obtains Antrodia Camphorata powder, standby；By Stigma Maydis, Eurycoma longifolia, Rhizoma Smilacis Glabrae
Siberian cocklebur and the proportional mixing of Semen Coicis, by water boiling and extraction three times, add water 10 times of weight every time, decocts 45 minutes, is extracted by gained
Liquid is condensed into immersion cream, and water content is 10wt%-15wt%, mixes with Antrodia Camphorata powder, and 85 DEG C are dried to dry cream；
Step 2): got dry extract for step 1) mixture is beaten powder, crosses 60 mesh sieves, after weighing, by powder: the matter of ethanol solution=5:1
Amount is than being slowly added to 70wt% ethanol solution, and stirring the most rapidly, the soft material obtained is with 12 mesh sieve wet granulations；
Step 3): by step 2) gained granule is slightly dried to alcohol taste at 105 DEG C and scatters and disappears, quickly with 12 mesh sieves arrangements, again exist
Dry at 105 DEG C, after cooling, carry out tabletting；Tablet format: every 0.5 gram.
The beneficial effects of the present invention is: Antrodia Camphorata has heat-clearing and toxic substances removing, eliminating carbuncle eliminating stagnation, lets out liver-fire, eliminating stasis to stop pain clearly
Effect, contained by it, Antrodia Camphorata polysaccharide can improve the immunologic function of body；Stigma Maydis has an inducing diuresis to remove edema, effect of suppressing the hyperactive liver function of gallbladder promoting,
Cure mainly edema, dribbling urination, jaundice, cholecystitis, cholelithiasis, hypertension, diabetes, galactostasis；Semen Coicis cures mainly insufficiency of the spleen
Rushing down, cause into edema, rheumatism dish delays, and causes into brothers unable, it is impossible to bend and stretch；Rhizoma Smilacis Glabrae has eliminating dampness and diuresis, invigorating the spleen and regulating the stomach, and mind calming is pacified
Effect of god；The natural phytochemicals of the probenecid that Eurycoma longifolia contains, can effectively regulate human endocrine, suppression
Uric acid synthesizes, and makes uric acid not be deposited in the positions such as human synovial, cartilage, soft tissue with the form of sodium salt crystal.The present invention is with cattle
Antrodia camphorata, Stigma Maydis are principal agent, are aided with Semen Coicis, Rhizoma Smilacis Glabrae, then the Eurycoma longifolia that compatibility uric acid resisting effect is stronger, between each composition
Cooperate, play cooperative effect, there is invigorating the spleen for eliminating dampness row turbid, increase uric acid and discharge the effect reaching uric acid resisting.
Detailed description of the invention
In order to make content of the present invention easily facilitate understanding, below in conjunction with detailed description of the invention to of the present invention
Technical scheme is described further, but the present invention is not limited only to this.
Embodiment 1
A kind of containing Antrodia Camphorata auxiliary uric acid resisting sheet, medicinal raw material used by it includes by weight: 1 part of Antrodia Camphorata powder, Stigma Maydis 7
Part, Eurycoma longifolia 3 parts, Rhizoma Smilacis Glabrae 1 part, Semen Coicis 2 parts.
Preparation method containing Antrodia Camphorata auxiliary uric acid resisting sheet comprises the steps: as mentioned above
Antrodia Camphorata is pulverized by step 1), crosses 80 mesh sieves, obtains Antrodia Camphorata powder, standby；By Stigma Maydis, Eurycoma longifolia, Rhizoma Smilacis Glabrae and
The proportional mixing of Semen Coicis, adds 10 times of crude drug weight, 10 times, 10 times of soak by water 3 times, and merging filtrate is dense in 68 DEG C of vacuum
Shortening thick paste (water content is 10wt%) into, mix with Antrodia Camphorata powder, 85 DEG C are dried to dry cream；
Step 2) got dry extract for step 1) mixture is beaten powder, cross 60 mesh sieves, after weighing, by powder: the matter of ethanol solution=5:1
Amount is than being slowly added to 70wt% ethanol, and stirring the most rapidly, the soft material obtained is with 12 mesh sieve wet granulations；
Step 3) is by step 2) gained granule is slightly dried to alcohol taste at 105 DEG C and scatters and disappears, quickly with 12 mesh sieves arrangements, again exist
Dry at 105 DEG C, after cooling, carry out tabletting；Tablet format: every 0.5 gram.
Embodiment 2
A kind of containing Antrodia Camphorata auxiliary uric acid resisting sheet, medicinal raw material used by it includes by weight: 2 parts of Antrodia Camphorata powder, Stigma Maydis 8
Part, Eurycoma longifolia 4 parts, Rhizoma Smilacis Glabrae 2 parts, Semen Coicis 3 parts.
Preparation method containing Antrodia Camphorata auxiliary uric acid resisting sheet comprises the steps: as mentioned above
Antrodia Camphorata is pulverized by step 1), crosses 90 mesh sieves, obtains Antrodia Camphorata powder, standby；By Stigma Maydis, Eurycoma longifolia, Rhizoma Smilacis Glabrae and
The proportional mixing of Semen Coicis, adds 10 times of crude drug weight, 10 times, 10 times of soak by water 3 times, and merging filtrate is dense in 68 DEG C of vacuum
Shortening thick paste (water content is 12wt%) into, mix with Antrodia Camphorata powder, 85 DEG C are dried to dry cream；
Step 2) got dry extract for step 1) mixture is beaten powder, cross 60 mesh sieves, after weighing, by powder: the matter of ethanol solution=5:1
Amount is than being slowly added to 70wt% ethanol, and stirring the most rapidly, the soft material obtained is with 12 mesh sieve wet granulations；
Step 3) is by step 2) gained granule is slightly dried to alcohol taste at 105 DEG C and scatters and disappears, quickly with 12 mesh sieves arrangements, again exist
Dry at 105 DEG C, after cooling, carry out tabletting；Tablet format: every 0.5 gram.
Embodiment 3
A kind of containing Antrodia Camphorata auxiliary uric acid resisting sheet, medicinal raw material used by it includes by weight: 3 parts of Antrodia Camphorata powder, Stigma Maydis
10 parts, Eurycoma longifolia 5 parts, Rhizoma Smilacis Glabrae 3 parts, Semen Coicis 4 parts.
Preparation method containing Antrodia Camphorata auxiliary uric acid resisting sheet comprises the steps: as mentioned above
Antrodia Camphorata is pulverized by step 1), crosses 100 mesh sieves, obtains Antrodia Camphorata powder, standby；By Stigma Maydis, Eurycoma longifolia, Rhizoma Smilacis Glabrae and
The proportional mixing of Semen Coicis, adds 10 times of crude drug weight, 10 times, 10 times of soak by water 3 times, and merging filtrate is dense in 68 DEG C of vacuum
Shortening thick paste (water content is 15wt%) into, mix with Antrodia Camphorata powder, 85 DEG C are dried to dry cream；
Step 2) got dry extract for step 1) mixture is beaten powder, cross 60 mesh sieves, after weighing, by powder: the matter of ethanol solution=5:1
Amount is than being slowly added to 70wt% ethanol, and stirring the most rapidly, the soft material obtained is with 12 mesh sieve wet granulations；
Step 3) is by step 2) gained granule is slightly dried to alcohol taste at 105 DEG C and scatters and disappears, quickly with 12 mesh sieves arrangements, again exist
Dry at 105 DEG C, after cooling, carry out tabletting；Tablet format: every 0.5 gram.
The present invention is containing the pharmacological testing of Antrodia Camphorata auxiliary uric acid resisting sheet
Experiment material
What 1.1 given the test agent preparation method as described in embodiment 2 obtained assists uric acid resisting sheet containing Antrodia Camphorata；Human body is recommended
Amount 2.5g/kg crude drug, is made into basic, normal, high 3 dosage by 5,10,20 times amount of human body recommended amounts, is configured to solution with pure water
(yellow liquid), standby.
1.2 Experimental Animals Male cleaning grade KM kind mices, body weight 18-22g；Had by Shanghai Si Laike laboratory animal
Limit responsible company provides, credit number: SCXK(Shanghai) 2012-0002.
1.3 instruments are produced by BIO-TEK company of the U.S. with reagent microplate reader, model ELx800；Wash trigger by the U.S.
BIO-TEK company produces, model ELx50.SUA, UUA, XOD ELISA kit is by R&D import subpackage.Yeast extract is by Beijing
Ao Boxing biotechnology Co., Ltd provides, lot number 20141001；Allopurinol tablet: public by The Place pharmacy Limited Liability
Department provides, lot number: 20140716；(SUA blood uric acid, UUA urinate acid, XOD liver xanthine oxidase)
Experimental technique
KM mice is randomly divided into 6 groups with being administered by 2.1 packets, often group 12.In addition to blank group, other are respectively organized and press 30g/kg agent
Amount gavage gives yeast extract, successive administration 7 days, causes metabolic arthritis model.Start model group from the 6th day and give normal saline, sun
Property group gives allopurinol tablet by 25mg/kg dosage gavage；Chinese medicine basic, normal, high dosage group, respectively according to 5, the 10 of human body recommended amounts
Times, 20 multiple dose gavages give given the test agent, once a day, continuous 5 days.Within 9th day, collect urine, within the tenth day, pluck eyeball blood sampling,
Take liver tissue homogenate.
2.2 observation index
2.2.1 Testing index SUA, UUA and XOD, uses Elisa method to measure.
Statistical method
Experimental data SPSS19.0 software carries out variance analysis, when variance is neat, uses between multiple experimental group and a matched group
The comparative approach two-by-two of mean carries out statistical analysis；During heterogeneity of variance, use rank test instead and add up.
Experimental result
Chinese medicine is on mice serum SUA, UUA excretion and the impact of liver XOD content.The SUA content of model control group is higher than sky
White group；Relatively there is significant difference (P < 0.01), Studies on Animal Models of Hyperuricemic Mice modeling success is described.The SUA of positive controls,
XOD content is significantly lower than model control group, difference statistically significant (P < 0.01)；The SUA content of Chinese medicine dosage group low, middle is bright
Aobvious less than model control group, difference statistically significant (P < 0.05)；Chinese medicine is low, the UUA content of high dose group is apparently higher than mould
Type matched group, difference statistically significant (P < 0.05)；Chinese medicine is low, the liver XOD content of high dose group is significantly lower than model comparison
Group, difference statistically significant (P < 0.01)；The results are shown in Table 1.
The impact (X ± S) on mice serum SUA, UUA excretion and liver XOD content of table 1 Chinese medicine
Note: * compares P < 0.05 with model control group;* compares P < 0.01 with model control group.
Experiment conclusion
Originally test result indicate that the auxiliary uric acid resisting sheet containing Antrodia Camphorata prepared by the present invention can effectively reduce hyperuricemia Mouse Blood
Clear SUA content；Promote that UUA excretion reduces liver XOD content simultaneously.
Conclusion
According to " drug registration administrative provisions ", the present invention can apply for having uric acid resisting Chinese medicine six kind new medicine.
The foregoing is only presently preferred embodiments of the present invention, all impartial changes done according to scope of the present invention patent with
Modify, all should belong to the covering scope of the present invention.
Claims (4)
1. one kind assists uric acid resisting sheet containing Antrodia Camphorata, it is characterised in that: medicinal raw material used includes by weight: Antrodia Camphorata powder
1-3 part, Stigma Maydis 7 ~ 10 parts, Eurycoma longifolia 3 ~ 5 parts, Rhizoma Smilacis Glabrae 1 ~ 3 part, Semen Coicis 2 ~ 4 parts.
It is the most according to claim 1 containing Antrodia Camphorata auxiliary uric acid resisting sheet, it is characterised in that: medicinal raw material used is by weight
Meter includes: 2 parts of Antrodia Camphorata powder, Stigma Maydis 8 parts, Eurycoma longifolia 4 parts, Rhizoma Smilacis Glabrae 2 parts, Semen Coicis 3 parts.
3. prepare the method containing Antrodia Camphorata auxiliary uric acid resisting sheet as claimed in claim 1 or 2 for one kind, it is characterised in that: include
Following steps:
Step 1): pulverized by Antrodia Camphorata, crosses 80-100 mesh sieve, obtains Antrodia Camphorata powder, standby；By Stigma Maydis, Eurycoma longifolia, Rhizoma Smilacis Glabrae
Siberian cocklebur and the proportional mixing of Semen Coicis, by water boiling and extraction three times, add water 10 times of weight every time, decocts 45 minutes, is extracted by gained
Liquid is condensed into immersion cream, mixes with Antrodia Camphorata powder, and 85 DEG C are dried to dry cream；
Step 2): got dry extract for step 1) mixture is beaten powder, crosses 60 mesh sieves, after weighing, by powder: the matter of ethanol solution=5:1
Amount is than being slowly added to 70wt% ethanol solution, and stirring the most rapidly, the soft material obtained is with 12 mesh sieve wet granulations；
Step 3): by step 2) gained granule is slightly dried to alcohol taste at 105 DEG C and scatters and disappears, quickly with 12 mesh sieves arrangements, again exist
Dry at 105 DEG C, after cooling, carry out tabletting；Tablet format: every 0.5 gram.
Preparation method containing Antrodia Camphorata auxiliary uric acid resisting sheet the most according to claim 3, it is characterised in that: wet in step 1)
Extractum water content is 10wt%-15wt%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610490926.2A CN105963595A (en) | 2016-06-28 | 2016-06-28 | Auxiliary uric acid reducing tablet with antrodia camphorata and method for preparing auxiliary uric acid reducing tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610490926.2A CN105963595A (en) | 2016-06-28 | 2016-06-28 | Auxiliary uric acid reducing tablet with antrodia camphorata and method for preparing auxiliary uric acid reducing tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963595A true CN105963595A (en) | 2016-09-28 |
Family
ID=57020092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610490926.2A Pending CN105963595A (en) | 2016-06-28 | 2016-06-28 | Auxiliary uric acid reducing tablet with antrodia camphorata and method for preparing auxiliary uric acid reducing tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963595A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110915970A (en) * | 2019-11-27 | 2020-03-27 | 江苏三仪生物工程有限公司 | Traditional Chinese medicine tablet candy capable of reducing urate deposition and preparation method thereof |
| CN115814028A (en) * | 2022-06-06 | 2023-03-21 | 重庆森康道生命健康研究院有限公司 | Uric acid reducing efficacy formula and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102151291A (en) * | 2010-01-19 | 2011-08-17 | 游介宙 | Use of antrodia camphorata for treating diseases |
| CN104012729A (en) * | 2014-06-11 | 2014-09-03 | 杨平 | Tea substitute bag capable of lowering uric acid |
| CN105031408A (en) * | 2015-08-27 | 2015-11-11 | 上海天慈国际药业有限公司 | Health product for improving gout |
-
2016
- 2016-06-28 CN CN201610490926.2A patent/CN105963595A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102151291A (en) * | 2010-01-19 | 2011-08-17 | 游介宙 | Use of antrodia camphorata for treating diseases |
| CN104012729A (en) * | 2014-06-11 | 2014-09-03 | 杨平 | Tea substitute bag capable of lowering uric acid |
| CN105031408A (en) * | 2015-08-27 | 2015-11-11 | 上海天慈国际药业有限公司 | Health product for improving gout |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110915970A (en) * | 2019-11-27 | 2020-03-27 | 江苏三仪生物工程有限公司 | Traditional Chinese medicine tablet candy capable of reducing urate deposition and preparation method thereof |
| CN115814028A (en) * | 2022-06-06 | 2023-03-21 | 重庆森康道生命健康研究院有限公司 | Uric acid reducing efficacy formula and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751529A (en) | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparation method thereof | |
| CN103463539A (en) | Drug for treating eczema, and preparation method and use thereof | |
| CN109045201B (en) | Traditional Chinese medicine composition for treating chronic digestive tract diseases with anxiety and depression states | |
| CN104162094A (en) | Traditional Chinese medicine composition for treating obese polycystic ovary syndrome, and medicinal preparation thereof | |
| CN102671178B (en) | Preparation method of Chinese medicinal composition for treating nephrotic syndrome and uremia and application thereof | |
| CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
| CN100528220C (en) | Gynecological Chinese patented medicine for relieving depressed liver and clearing heat, strengthening spleen and nourishing blood and its preparing method | |
| CN105963595A (en) | Auxiliary uric acid reducing tablet with antrodia camphorata and method for preparing auxiliary uric acid reducing tablet | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN103272119A (en) | Traditional Chinese medicine preparation for treating osteoporosis | |
| CN1879838A (en) | A Chinese medicine for treating threatened abortion | |
| CN102293923B (en) | Application of Tibetan medicinal composition to preparation of medicament for preventing and treating osteoporosis | |
| CN108853427A (en) | Traditional Chinese medicine prescription for treating overweight/obesity type polycystic ovarian syndrome | |
| CN103877554B (en) | Pharmaceutical composition for treating heart disease and preparation method and use thereof | |
| CN106177712A (en) | A kind of magnificent Bulbus Allii bean treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN105362645A (en) | Preparation method of pharmaceutical composition for treating oral inflammations | |
| CN102274442B (en) | Deer bone wine for treating arthralgia syndrome and preparation method and application thereof | |
| CN103272029A (en) | Traditional Chinese medicine formula for curing hypertension | |
| CN102614380B (en) | Traditional Chinese medicinal composition pulvis and tablets for treating primary osteoporosis, preparation method thereof and health-care product | |
| CN105641057A (en) | Medicine composition for treating primary glomerular hematuria caused by failure of spleen to control blood vessels | |
| CN104940478A (en) | Ginseng antler brain-nourishing prescription for treating AD diseases | |
| CN104606442B (en) | A kind of Chinese medicine composition treating deficiency of kidney-essence type postmenopausal osteoporosis | |
| CN103920133A (en) | Traditional Chinese medicine application and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |